What is Corvus Pharmaceuticals, Inc. (CRVS) stock price today?

Corvus Pharmaceuticals, Inc. (CRVS) is currently trading at $10.52, up 3.04% today.

What is CRVS P/E ratio?

Corvus Pharmaceuticals, Inc.'s P/E ratio is -17.03. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is CRVS return on equity (ROE)?

Corvus Pharmaceuticals, Inc.'s return on equity (ROE) is -36.15%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is Corvus Pharmaceuticals, Inc.'s market cap?

Corvus Pharmaceuticals, Inc. has a market capitalization of $884.63M.

NASDAQ · Biotechnology

Corvus Pharmaceuticals, Inc. (CRVS) Stock

$10.52 +3.04% NASDAQ: CRVS Healthcare

Valuation

Metric	Value
Price	$10.52
Market Cap	$884.63M
P/E Ratio	-17.03
P/B Ratio	4.47
P/S Ratio	0.00
EPS (TTM)	$0.00
52-Week High	$26.95
52-Week Low	$6.39
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-36.15%
ROA	-22.62%
ROCE	-25.25%
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Debt/Equity	0.02
Current Ratio	6.44

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$0	$0	$0	$0	$0
Operating Profit	$-39.0M	$-33.0M	$-23.0M	$-28.0M	$-43.0M
Net Profit	$-43.0M	$-41.0M	$-27.0M	$-62.0M	$-15.0M
EPS	$-1.03	$-0.89	$-0.56	$-1.02	$-0.53
Op Margin	—	—	—	—	—

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$109.0M	$68.0M	$46.0M	$69.0M	$71.0M
Total Liabilities	$12.0M	$12.0M	$7.0M	$36.0M	$10.0M
Cash	$63.0M	$13.0M	$13.0M	$9.0M	$5.0M
Borrowings	$4.0M	$3.0M	$1.0M	$1.0M	$1.0M

Latest News

Corvus Pharmaceuticals Director Buys 21,700 Shares. Does This Mean CRVS a Buy? Motley Fool · Jun 23, 2026 Corvus Pharmaceuticals Faces Key Soquelitinib Data And Possible M&A Interest Simply Wall St. · Jun 14, 2026 Is Corvus Pharmaceuticals, Inc. (CRVS) A Good Stock To Buy Now? Insider Monkey · Jun 13, 2026 Corvus Pharmaceuticals Announces Additional Investment in Angel Pharmaceuticals to Advance the Development of Soquelitinib in China GlobeNewswire · Jun 9, 2026 Adams Street Partners Exits Its 223,000-Share Paymentus (PAY) Position for $5.9 Million Motley Fool · May 24, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-37.0M	$-27.0M	$-24.0M	$-25.0M	$-33.0M
Investing Cash Flow	$22.0M	$-24.0M	$16.0M	$-27.0M	$-8.0M
Financing Cash Flow	$1.0M	$0	$0	$33.0M	$0
Net Cash Flow	$47.0M	$-50.0M	$-1.0M	$-4.0M	$-4.0M
Free Cash Flow	$-37.0M	$-27.0M	$-24.0M	$-25.0M	$-33.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.07
EV / EBITDA	-17.45
FCF Yield	-4.93%
Quick Ratio	16.16
Interest Coverage	-31.93
Return 1Y	192.93%
Return 3Y	465.29%
Return 5Y	542.49%

Ownership

Insiders Held3.51%

Institutions Held85.57%

Institutions Float Held88.68%

Institutional Holder	Shares	Report Date
Orbimed Advisors LLC.	7,165,006	2026-03-31
Blackrock Inc.	6,160,422	2026-03-31
State Street Corporation	3,565,992	2026-03-31
Adams Street Partners, LLC	3,275,616	2026-03-31
Vanguard Capital Management LLC	3,234,538	2026-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
ADAGAdagene Inc.	$3.67	+1.66%	-7.78	$138.17M	0.00%
CGENCompugen Ltd.	$2.13	+0.47%	6.15	$201.40M	0.00%
CHRSCoherus Oncology, Inc.	$1.07	+0.00%	-1.10	$165.32M	0.00%
CMPXCompass Therapeutics, Inc.	$0.99	+0.98%	-2.06	$178.83M	0.00%
CTMXCytomX Therapeutics, Inc.	$2.57	+4.05%	-5.69	$559.50M	0.00%

About Corvus Pharmaceuticals, Inc.

Corvus Pharmaceuticals, Inc. is led by CEO Richard A. Miller, employs 31 people, headquartered in US, publicly traded since 2016.

Corvus Pharmaceuticals, Inc. (CRVS) stock trades at $10.52 with a market capitalization of $884.63M. The stock is valued at a price-to-earnings (P/E) ratio of -17.03, price-to-book of 4.47, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $6.39 and $26.95, and currently trades 61.0% below its 52-week high.

On profitability, Corvus Pharmaceuticals, Inc. generates a return on equity (ROE) of -36.15%, return on capital employed of -25.25%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides